Clinical trials: Attention Deficit Disorder With Hyperactivity
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00962104
- Testing
- Atomoxetine
- Where
- 24 sites in Japan, South Korea and 1 more
- Volunteers
- 391 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed behavioral disorder in children. Prevalence rates in the United States range from 2% to 18% depending on diagnostic criteria and population studied.
- Trial name
- NCT01351064
- Testing
- CHICA ADHD Module
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Indiana University
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Attention Deficit Hyperactivity Disorder
Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community
The American Academy of Pediatrics (AAP) has established a set of consensus guidelines for pediatricians to follow. These guidelines can be challenging to implement in typical community-based practices.
- Trial name
- NCT01056016
- Testing
- ADHD Collaborative
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Lisdexamfetamine's Effect In ADHD in the Brain and Cognition
The purpose of this study is to identify the effects of lisdexamfetamine (LDX) on the neural and behavioral subcomponents of self-control, that is cognitive control and reward functioning, in adolescents and young adults with…
- Trial name
- LEIA (NCT02170298)
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
ADHD
The Effects of ADHD Medication (TEAM) Study
This study evaluates the effects of receiving and then discontinuing methylphenidate (MPH) in children with ADHD. After receiving MPH for 8 weeks, participants will be randomized to either discontinue MPH (and receive placebo) OR…
- Trial name
- TEAM (NCT02293655)
- Testing
- OROS-Methylphenidate (MPH)
- Where
- 2 sites in United States
- Volunteers
- 204 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
This study will determine whether two new psychostimulant medications are more effective, tolerable, and acceptable than two older medications for treating attention deficit hyperactivity disorder.
- Trial name
- NCT00889915
- Testing
- Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH)
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Duke University
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are considered risk factors for subsequent substance abuse, and youth with both ADHD and ODD/CD are at greatest risk.
- Conditions
- Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Substance Abuse
- Trial name
- NCT04170738
- Testing
- Adderall
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jeffrey Newcorn
Attention Deficit Disorder
Neurofeedback and Working Memory Training for Children and Adolescents With ADHD
The purpose of this study is to investigate if neurofeedback and working memory training improves core symptoms of ADHD in children and adolescents.
- Trial name
- KITE (NCT01841151)
- Testing
- SCP training, Live Z-score training, WM training
- Where
- Sweden
- Volunteers
- 202 people
- Sponsor
- Karolinska Institutet
ADHD
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
- Trial name
- NCT00697515
- Testing
- LDX
- Where
- 5 sites in United States
- Volunteers
- 142 people
- Sponsor
- Shire
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication.
- Trial name
- DoDNAC (NCT04481048)
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects
This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD.
- Trial name
- NCT00995085
- Testing
- Extended Release Metadoxine
- Where
- Israel
- Volunteers
- 43 people
- Sponsor
- Alcobra Ltd.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a…
- Trial name
- NCT01107496
- Testing
- IR Viloxazine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD
- Trial name
- NCT03247556
- Testing
- 400mg SPN-812, 600mg SPN-812
- Where
- 14 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder Symptoms
Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test
The purpose of this study is to pilot test for feasibility and initial promise an implementation strategy resource package that aims to support teachers in using behavioral classroom management interventions for children with…
- Trial name
- NCT05489081
- Testing
- Positive Behavior Management Toolkit
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia